 |  |  |  |  |
| | | | |
Many small efforts put together can change the world. With each achievement and accomplishment we contribute in our way. Our strong commitment brings us closer to our goals every day.
Are you going to make a statement for those with Rare Diseases ?!
We welcome any support you can give and look forward to receiving word from you.
Would you like to get our printed flyer?
You can order the following flyer
- Flyer Company
- Flyer Foundation
Please send us an email and place your order. If you don't forget to give us your adresse we will send them by post.
The conventional model of traditional pharmaceutical companies needs to be questioned. This is because Health is a chartered right (a statement of he UN Health Organisation (pdf)), and the current important issue of bettering health for people affected by a Rare Disease is not being addressed thoroughly. We hold the view that there needs to be additional new and alternative business models for the complex issues and needs of the 21st century. For us, one of these issues is the morality of decisions.
The traditional pharmaceutical research today is very expensive and extremely lengthy. It takes on average, 12 years from the molecular discovery for a finished product to hit the market. For a new medication (about 1 substance out of 40,000 tested), pharmaceutical giants will pay out nearly more than 500 million Euros all at once. Also to consider are the high requirements for the application and registering of new drugs. Medicine has to be not only be affective, but also safe.
We however can proceed much faster and at a lower cost than the pharmaceutical giants. How is this possible? The Orphan Drug Act of 1983, later also recognised in the EU and Switzerland allows for this. More Info
Large pharmaceutical companies are focused on diseases that affect a large amount of people. This is because of their elaborate infrastructure and hefty research costs. They affix themselves to so-called „Blockbusters” and Lifestyle Medications so that invested capital and the decision often follows market trends to increase the stock prices of the company.
This creates a situation where Rare Diseases are barely considered or don’t even have any treatment options. With our structure we are able to consciously keep our costs relatively low. Furthermore, we are not only looking at dividends as the reason to push a new medication forward. We also consider the philanthropic grounds to develop a new medication.
For these reasons, we are not looking for the „typical investor” who is generally only concerned with returns on investment. Our business model appeals to investors who are interested in philanthropic ideas and investments.
Because we think that those affected by Rare Disease also have the right to adequate treatment.